A Study of Tolerability, Satisfaction, and Cost Reduction Using a 10% Immunoglobulin Product at Higher Administration...

Area of Science:

• Immunology
• Pharmacology
• Health Economics

Background:

• Intravenous immunoglobulin (IVIG) is a critical therapy for various conditions.
• Traditional IVIG infusion protocols can be lengthy and costly.
• Gammaplex 10% offers a potential for more efficient administration.

Purpose of the Study:

• To evaluate the safety and efficacy of rapid infusion of Gammaplex 10% (immune globulin intravenous [human]).
• To assess patient satisfaction with the rapid infusion protocol.
• To determine the cost savings associated with rapid Gammaplex 10% administration.

Main Methods:

• Analysis of safety, patient satisfaction, and cost data from 49 patients over 11 months.
• Utilized a 15-minute rate-escalation protocol for Gammaplex 10% infusions.
• Compared rapid infusion outcomes to previous standard IVIG infusion methods.

Main Results:

• 38 adverse reactions reported in 14 patients, with 37 classified as minor/moderate, indicating a favorable safety profile.
• Patient satisfaction was rated as very good/outstanding.
• Infusions were 2.4 hours shorter, resulting in estimated nursing cost savings of $151.61 per visit.

Conclusions:

• Rapid infusion of Gammaplex 10% is a safe and well-tolerated method for IVIG administration.
• This approach significantly reduces treatment duration and healthcare costs.
• Gammaplex 10% rapid infusion maintains high patient satisfaction, offering a cost-effective alternative for IVIG therapy.